# Ulimorelin Study of Efficacy and Safety (ULISES 007)

> **NCT01285570** · PHASE3 · COMPLETED · sponsor: **Tranzyme, Inc.** · enrollment: 332 (actual)

## Conditions studied

- Gastrointestinal Dysmotility

## Interventions

- **DRUG:** Ulimorelin Intravenously (IV)
- **DRUG:** Ulimorelin Intravenously (IV)
- **DRUG:** 5% dextrose in water

## Key facts

- **NCT ID:** NCT01285570
- **Lead sponsor:** Tranzyme, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 332 (ACTUAL)
- **Last updated:** 2012-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01285570

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01285570, "Ulimorelin Study of Efficacy and Safety (ULISES 007)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01285570. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*